From: The composition of the pulmonary microbiota in sarcoidosis – an observational study
Clinical characteristics | Sarcoidosis | Interstitial lung disease | p-value |
---|---|---|---|
Number of subjects, n (%) | 31 (62%) | 19 (38%) | – |
Female, n (%) | 14 (45%) | 8 (42%) | – |
Male, n (%) | 17 (55%) | 11 (58%) | – |
Age (years), median (range) | 51 (22–79) | 66 (57–82) | 0.0003 |
Smoking | |||
Non-smokers, n (%) | 18 (58%) | 6 (31.5%) | 0.06 |
Current-smokers, n (%) | 7 (22.5%) | 2 (10.5%) | 0.25 |
Former-smokers, n (%) | 6 (19.5%) | 9 (47%) | 0.05 |
BMI, median (range) | 27 (17–37.1) | 24.7 (16.8–34.9) | 0.5 |
Pulmonary function test | |||
FEV1%, median (range) | 81.5 (61.5–126.8) | 66.8 (49–109.6) | 0.66 |
FEV1/VC, median (range) | 79.8 (66.2–86.5) | 85.7 (61.4–108.8) | 0.02 |
TLC (l), median (range) | 5.54 (4.17–8.38) | 4.2 (2.56–7.99) | 0.26 |
ERV (l), median (range) | 0.78 (0.21–1.39) | 0.55 (0.12–1.97) | 0.89 |
RV (l), median (range) | 2.12 (1.12–4.54) | 1.76 (1.41–2.87) | 0.60 |
VC (l), median (range) | 3.34 (1.9–5.61) | 2.34 (0.88–5.6) | 0.26 |
Bronchoscopy, BAL | |||
BAL recovery %, median | 50 | 55 | |
Neutrophils %, median | 9 | 14 | 0.05 |
Macrophages %, median | 49 | 62 | 0.01 |
Lymphocytes %, median | 38 | 25.5 | 0.02 |
Eosinophils %, median | 1 | 2 | 0.19 |
Basophils %, median | 0 | 0 | |
CD4/CD8 ratio, median | 3.2 | 0.8 | 0.03 |
Laboratory | |||
CRP mg/dl, median (range) | 4.2 (0.4–83.9) | 5.4 (0.6–326.3) | 0.44 |
Leukocytes (1/μl), median (range) | 5.65 (3–13.8) | 7.55 (3.4–13.9) 0.12 |